Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study-Reference-Cited by-同舟云学术

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Published:2020-03 Issue:3 Volume:21 Page:373-386
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Sequist Lecia V,Han Ji-Youn,Ahn Myung-Ju,Cho Byoung Chul,Yu Helena,Kim Sang-We,Yang James Chih-Hsin,Lee Jong Seok,Su Wu-Chou,Kowalski Dariusz,Orlov Sergey,Cantarini Mireille,Verheijen Remy B,Mellemgaard Anders,Ottesen Lone,Frewer Paul,Ou Xiaoling,Oxnard Geoffrey

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update;Hanna;J Clin Oncol,2017

2. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

3. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers;Yu;Clin Cancer Res,2013

4. LBA51 analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study;Papadimitrakopoulou;Ann Oncol,2018

5. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib;Oxnard;JAMA Oncol,2018

Cited by 315 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis;ESMO Open;2024-09

2. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer;European Journal of Cancer;2024-09

3. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

4. Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment;International Journal of Molecular Sciences;2024-08-22

5. Case report: A case of Savolitinib in the treatment of MET amplification mutation advanced lung adenocarcinoma with rare bilateral breast metastasis;Frontiers in Oncology;2024-08-13